Skip to main content
OpenTrials
Completed

NCT Number: NCT03457012

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by the study doctor. The study will last for about 6 to 8 months. Participants will be asked to complete some questionnaires about the health and the diabetes treatment. Participants will complete these during the normally scheduled visits with the study doctor.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Novo Nordisk Investigational Site

Cambridge, Ontario, N1R 7L6, Canada

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
  • The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
  • Male or female, age greater than or equal to 18 years at the time of signing informed consent
  • Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion
  • Available and documented HbA1c value less than or equal to 12 weeks prior to initiation of semaglutide treatment

Exclusion criteria

  • Previous participation in this study. Participation is defined as having given informed consent in this study
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • Treatment with any investigational drug within 90 days prior to enrolment into the study
  • Hypersensitivity to semaglutide or to any of the excipients

Treatment and study plan

semaglutide

Drug

Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.

Primary outcomes

  1. Change in Glycated Haemoglobin A1c (HbA1c)

    Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)

    Measured in % points

  2. Change in HbA1c

    Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)

    Measured in mmol/mol

Secondary outcomes

  1. Change in body weight

    Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)

    Measured in kg

  2. Change in body weight

    Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)

    Measured in %

  3. Change in waist circumference

    Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)

    Measured in cm

  4. HbA1c level at end of study: < 8.0% (64 mmol/mol) (yes/no)

    Time frame: At end of study (week 28-38)

    Number of participants who achieved/not achieved HbA1c level at end of study: <8.0%

  5. HbA1c level at end of study: <7.5% (59 mmol/mol) (yes/no)

    Time frame: At end of study (week 28-38)

    Number of participants who achieved/not achieved HbA1c level at end of study: <7.5%

  6. HbA1c level at end of study: <7.0% (53 mmol/mol) (yes/no)

    Time frame: At end of study (week 28-38)

    Number of participants who achieved/not achieved HbA1c level at end of study: <7.0%

  7. Reduction in HbA1c of 1.0% point or more (yes/no)

    Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)

    Number of participants who achieved/not achieved reduction in HbA1c of 1.0% point or more

  8. Weight reduction of 3.0% or more (yes/no)

    Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)

    Number of participants who achieved/not achieved weight reduction of 3.0% or more

  9. Weight reduction of 5.0% or more (yes/no)

    Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)

    Number of participants who achieved/not achieved weight reduction of 5.0% or more

  10. HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)

    Time frame: Baseline (up to 12 weeks prior to treatment initiation at week 0), end of study (week 28-38)

    Number of participants who achieved/not achieved HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more

  11. Patient reported severe or documented hypoglycaemia (yes/no)

    Time frame: Between baseline (week 0) and end of study (week 28-38)

    Number of participants who reported/not reported severe or documented hypogycaemia

  12. Change in Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction

    Time frame: Baseline (week 0), end of study (week 28-38)

    The status version (DTSQs) provides a measure of how satisfied patients are with their current diabetes treatment. It consists of 8 questions, which are to be answered on a Likert scale from 0 to 6 (0 = very dissatisfied to 6 = very satisfied). Six questions are summed to produce a total Treatment Satisfaction score. The remaining two questions are concerning perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia, respectively.

  13. Change in Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction

    Time frame: Baseline (week 0), end of study (week 28-38)

    The change version (DTSQc) has the same 8 items as the status version, but is reworded to direct the patients to compare the experience of the current treatment with the experience of previous treatment. Each question is scored on a scale of -3 to +3 (-3 = much less satisfied now to +3 = much more satisfied now), with 0 (midpoint), representing no change.

  14. Change in Short Form (SF)-36 v2: Physical summary component

    Time frame: Baseline (week 0), end of study (week 28-38)

    The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health).

  15. Change in SF-36 v2: Mental summary component

    Time frame: Baseline (week 0), end of study (week 28-38)

    The SF-36®v2 questionnaire has 36 questions grouped into eight domains termed: physical functioning, bodily pain, role-physical, general health, vitality, social functioning, role-emotional and mental health, which again can be combined to give two summary component scores (overall mental- and physical health).

  16. Patient completed the study under treatment with semaglutide (yes/no)

    Time frame: At end of study (week 28-38)

    Number of patients who completed/not completed the study under treatment with semaglutide

Sponsors and collaborators

Lead sponsor

Novo Nordisk A/S

Industry

Registry information

Official study title

SURE CANADA: A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once Weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes

Acronym: SURE CANADA

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Mar 7, 2018
Registry last updated
Sep 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.